Abstract | BACKGROUND: OBJECTIVE: METHODS: This is a retrospective review of 311 aneurysms from 297 patients who underwent stent-assisted endovascular coil embolization of unruptured intracranial aneurysm between November 2014 and March 2017. Thromboembolic and hemorrhagic adverse events were compared between 207 patients who received low-dose prasugrel (PSG group) and 90 patients who received clopidogrel (CPG group). RESULTS: P2Y12 reaction unit (PRU) values were significantly lower in the PSG group (PSG group vs CPG group, 132.3 ± 76.9 vs 238.1 ± 69.1; P < .001); the percentage of inhibition was also statistically higher in the PSG group (54.0 ± 26.0% vs 20.8 ± 18.6%; P < .001). Thromboembolic events occurred less frequently in the PSG group than in the CPG group (0.9% vs 6.4%; P = .01), whereas there was no significant difference in the percentage of hemorrhagic complications (0.5% vs 2.2%; P = .22). In the multivariate analysis, clopidogrel as the antiplatelet medication was the sole significant risk factor for thromboembolism in this series of patients undergoing stent-assisted coil embolization. CONCLUSION:
|
Authors | Hyun Ho Choi, Jung Jun Lee, Young Dae Cho, Moon Hee Han, Won-Sang Cho, Jeong Eun Kim, Sang Joon An, Jong Hyeon Mun, Dong Hyun Yoo, Hyun-Seung Kang |
Journal | Neurosurgery
(Neurosurgery)
Vol. 83
Issue 5
Pg. 981-988
(11 01 2018)
ISSN: 1524-4040 [Electronic] United States |
PMID | 29301051
(Publication Type: Journal Article)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Prasugrel Hydrochloride
|
Topics |
- Adult
- Aged
- Clopidogrel
(therapeutic use)
- Embolization, Therapeutic
(adverse effects)
- Endovascular Procedures
(adverse effects)
- Female
- Humans
- Intracranial Aneurysm
(complications, surgery)
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prasugrel Hydrochloride
(therapeutic use)
- Premedication
(methods)
- Retrospective Studies
- Risk Factors
- Stents
- Thromboembolism
(etiology, prevention & control)
|